AstraZeneca has agreed a deal worth up to $ ... The partnership also comes amid a flurry of other news about the application of GenAI techniques to the discovery and development of large-molecule ...

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and $9 price target.

Absci Corporation’s ABSI share price has surged by 17.57%, which has investors questioning if this is right time to sell.

This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates.

"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

This collaboration builds on Absci’s growing portfolio of partnerships with industry leaders such as AstraZeneca and Merck, as well as its robust internal pipeline of drug candidates. With this new ...